Ofanoa Samuela, Ofanoa Malakai, Tu'akoi Siobhan, Lutui Hinamaha, Heather Maryann, Jansen Rawiri McKree, Dalbeth Nicola, Grey Corina, Goodyear-Smith Felicity
Pacific Health Section, University of Auckland, Auckland, New Zealand.
Alliance Health Plus, Mount Wellington, Auckland, New Zealand.
J Prim Health Care. 2023 Mar;15(1):48-58. doi: 10.1071/HC22094.
Introduction Gout in Aotearoa New Zealand (NZ) remains an equity issue. The prevalence in Pacific and Māori people is one of the highest internationally. Although Pacific and Māori experience earlier onset and higher burden of gout, which can severely impact their quality of life, their management of it is often sub-optimal. Aim To conduct a scoping review of the NZ literature for interventions to improve the uptake/management of allopurinol for gout and their evaluation. Methods Databases Medline, Scopus, Embase, and CINAHL Plus and the grey literature were searched systematically to identify all NZ intervention studies aiming to improve allopurinol uptake for gout treatment. Interventions included: if they were delivered in NZ, aimed to improve allopurinol uptake, and were provided in English. A narrative approach was used to extract and synthesise data. Results Eighteen peer-reviewed and grey literature publications met the search criteria. Interventions clustered into three domains: multifaceted or multi-practitioner; gout app; and online booklets or fact sheets. Serum urate levels improved in multi-faceted or multi-practitioner interventions only, whereas the gout app only improved patients' awareness and understanding of gout and medications. Online fact sheets and booklets need more active utilisation from health professionals to improve gout health literacy. Discussion Most gout interventions in NZ use multifaceted or multi-practitioner approaches. Although most interventions successfully controlled serum urate levels and improved equitable access for gout patients to urate-lowering therapy, these interventions did not sustain retention, completion, and engagement for certain population groups, particularly Pacific and Māori, who experience a higher burden of gout.
引言
在新西兰,痛风仍然是一个公平性问题。太平洋岛民和毛利人的痛风患病率在国际上处于最高水平之一。尽管太平洋岛民和毛利人痛风发病更早且负担更重,这会严重影响他们的生活质量,但他们对痛风的管理往往不尽人意。
目的
对新西兰文献进行范围综述,以探究改善痛风患者别嘌醇使用情况/管理的干预措施及其评估。
方法
系统检索数据库Medline、Scopus、Embase和CINAHL Plus以及灰色文献,以识别所有旨在改善痛风治疗中别嘌醇使用情况的新西兰干预研究。干预措施包括:在新西兰实施、旨在提高别嘌醇使用情况且以英文提供。采用叙述性方法提取和综合数据。
结果
18篇同行评议和灰色文献出版物符合检索标准。干预措施分为三个领域:多方面或多从业者;痛风应用程序;以及在线手册或情况说明书。仅多方面或多从业者干预措施能改善血清尿酸水平,而痛风应用程序仅提高了患者对痛风和药物的认识与理解。在线情况说明书和手册需要卫生专业人员更积极地利用,以提高痛风健康素养。
讨论
新西兰大多数痛风干预措施采用多方面或多从业者方法。尽管大多数干预措施成功控制了血清尿酸水平,并改善了痛风患者获得降尿酸治疗的公平性,但这些干预措施未能维持某些人群,特别是痛风负担较重的太平洋岛民和毛利人的留存率、完成率和参与度。